Welcome to our dedicated page for Roivant Sciences Ltd. SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Roivant Sciences Ltd. filings document material events for a Nasdaq-listed Bermuda biopharmaceutical company with common shares registered under the ticker ROIV. The company’s recent Form 8-K disclosures cover quarterly financial results, preliminary liquidity information, share repurchases, Regulation FD updates and exhibits tied to clinical programs at subsidiaries such as Priovant Therapeutics.
Its filings also record material definitive agreements and amendments, including the Genevant Sciences settlement agreement involving lipid nanoparticle delivery technology, as well as shareholder voting results from the annual general meeting. Governance disclosures include director elections, auditor ratification and other proxy-related voting matters, while clinical exhibits describe programs such as brepocitinib in autoimmune and inflammatory diseases.
Roivant Sciences Ltd. (ROIV) reported that director Daniel Allen Gold had 5,133 Common Shares withheld on September 10, 2026 to satisfy tax withholding obligations in connection with the vesting and settlement of previously granted shares under the Non-Employee Director Compensation Plan. After this net-share tax withholding, he holds 8,960,761 Common Shares directly.
Roivant Sciences Ltd. (ROIV) director Oren Ilan reported a disposition of 2,378 Common Shares of the company on September 10, 2026. The shares were withheld by the issuer as a net settlement to cover applicable tax withholding obligations upon vesting of previously granted director equity awards. Following this tax-withholding transaction, Ilan directly holds 118,626 Common Shares of Roivant Sciences Ltd. No transactions were reported under a Rule 10b5-1 trading plan.
Roivant Sciences Ltd. (ROIV) reported that director Melissa B. Epperly had 2,179 Common Shares withheld on September 10, 2026, as a tax-withholding disposition connected to the vesting and settlement of previously granted shares under the Non-Employee Director Compensation Plan. After this net-share settlement for tax liabilities, she directly holds 14,838 Common Shares.
Roivant Sciences Ltd. (ROIV) director Meghan Fitzgerald had 1,743 Common Shares withheld on September 10, 2026 as a net settlement to satisfy tax withholding obligations tied to vesting of previously granted director equity awards. The shares were valued at $40.94 per share, leaving her with 41,220 Common Shares held directly after this transaction. No Rule 10b5-1 trading plan is reported for this disposition.
Roivant Sciences Ltd. (ROIV) director James C. Momtazee reported a Form 4 transaction involving the withholding of 2,905 Common Shares on September 10, 2026. The shares were withheld at $40.94 per share to satisfy tax withholding obligations upon vesting of equity granted under the company’s Non-Employee Director Compensation Plan, leaving him with 106,905 Common Shares held directly.
Roivant Sciences Ltd. (ROIV) director Meghan Fitzgerald reported an option exercise and same-day sale of common shares. On September 8, 2026, she exercised options for 20,000 shares at $8.80 per share, then sold 20,000 common shares at a weighted average price between $39.90 and $40.00 per share under a Rule 10b5-1 trading plan. Following the exercise, she held 18,578 stock options that remain exercisable until April 19, 2033.
Roivant Sciences Ltd. (ROIV) director Meghan Fitzgerald filed a notice of proposed sales under Rule 144. The filing covers 20,000 common shares to be sold through Morgan Stanley Smith Barney, arising from an exercise of stock options for cash on September 8, 2026, with an aggregate market value of $698,600. The disclosure also notes that during the prior three months, Rule 10b5-1 sales by Meghan Fitzgerald included 10,000 common shares on June 30, 2026 for $349,000.
Roivant Sciences Ltd. (ROIV) reported positive topline results from its Phase 2 PHocus trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD) and has initiated the Phase 3 PHrontier trial. PH-ILD is described as a progressive, life‑threatening condition with significant unmet medical need.
PHocus met its primary endpoint with a placebo‑adjusted pulmonary vascular resistance (PVR) reduction of 56.3% at Week 16 (‑51.3% mosliciguat vs. +6.6% placebo; p<0.0001). Key secondary endpoints also favored mosliciguat, including a placebo‑adjusted improvement in six‑minute walk distance of 35.2 meters at Week 16 (p=0.0027) and a placebo‑adjusted NT‑proBNP reduction of 357.7 pg/mL, corresponding to a 53.2% decline from baseline (p=0.0002). Exploratory Week 24 data showed further gains in walk distance (+52.7 meters) and NT‑proBNP (‑487.1 pg/mL; ‑75.9%).
Mosliciguat was observed to be well tolerated with adverse events consistent with PH‑ILD; cough incidence was 12.1% on mosliciguat versus 18.2% on placebo. The global Phase 2 study enrolled 135 patients across 87 sites in 20 countries, and the Phase 3 PHrontier trial is planned to enroll approximately 375 patients with PH‑ILD.
Roivant Sciences Ltd. (ROIV) reported that officer Eric Venker, President & Immunovant CEO, exercised stock options for 200,000 Common Shares at an exercise price of $3.85 per share and on the same date sold an aggregate of 200,000 Common Shares in multiple transactions at weighted average prices of $35.63 and $36.44 per share, under a Rule 10b5-1 trading plan adopted on March 28, 2025. Following the option exercise, Venker reported 3,844,834 stock options remaining directly held.
Roivant Sciences Ltd. (ROIV) received a notice that Eric Venker plans to sell up to 200,000 common shares of Roivant under Rule 144. The planned sale is scheduled for 08/28/2026 on NASDAQ and will be executed via Rockefeller Financial LLC under a Rule 10b5-1 trading plan adopted on 03/28/2025.
Roivant reports that its common shares outstanding were 719,270,385 as of this notice, a baseline figure, not the amount being sold. In the prior three months, Venker has sold additional Roivant shares in three transactions totaling several hundred thousand shares.